Medtech Insight Podcasts https://insights.citeline.com/medtech-insight/ en All rights reserved Medtech Insight takes device and diagnostics stakeholders inside the trends shaping global medical technology. Featuring Digital Health Roundup and other series, expert journalists unpack digital health, device approvals, policy shifts and market dynamics. Stay ahead at https://insights.citeline.com/medtech-insight with newsletters and daily updates on the evolving device and diagnostics landscape. For any podcast feedback or queries, you can now reach us at podcasts@norstella.com. https://megaphone.imgix.net/podcasts/f5700d2e-31a8-11f1-92d0-071db141f0e3/image/ea5cc2f754b801e4067b1d563cdc7dcc.png?ixlib=rails-4.3.1&max-w=3000&max-h=3000&fit=crop&auto=format,compress Medtech Insight Podcasts https://insights.citeline.com/medtech-insight/ episodic Norstella Medtech Insight takes device and diagnostics stakeholders inside the trends shaping global medical technology. Featuring Digital Health Roundup and other series, expert journalists unpack digital health, device approvals, policy shifts and market dynamics. Stay ahead at https://insights.citeline.com/medtech-insight with newsletters and daily updates on the evolving device and diagnostics landscape. For any podcast feedback or queries, you can now reach us at podcasts@norstella.com. Medtech Insight takes device and diagnostics stakeholders inside the trends shaping global medical technology. Featuring Digital Health Roundup and other series, expert journalists unpack digital health, device approvals, policy shifts and market dynamics. Stay ahead at https://insights.citeline.com/medtech-insight with newsletters and daily updates on the evolving device and diagnostics landscape. For any podcast feedback or queries, you can now reach us at podcasts@norstella.com.

]]> Norstella webpubs@citeline.com Digital Health Roundup: BD’s $19Bn Tariff Deal, Longevity, GLP-1 Tools Chasing Proof In this month's podcast, Shubham Singh discusses BD’s $19bn US investment deal for tariff relief; Brian Bossetta, NET Recovery’s stimulant-use device; George Underwood, Reset Health’s GLP-1 adherence data; and Marion Webb, Hillary Lin’s evidence-based longevity care; Thu, 15 Oct 2026 05:33:00 -0000 full Norstella In this month's podcast, Shubham Singh discusses BD’s $19bn US investment deal for tariff relief; Brian Bossetta, NET Recovery’s stimulant-use device; George Underwood, Reset Health’s GLP-1 adherence data; and Marion Webb, Hillary Lin’s evidence-based longevity care; In this month's podcast, Shubham Singh discusses BD’s $19bn US investment deal for tariff relief; Brian Bossetta, NET Recovery’s stimulant-use device; George Underwood, Reset Health’s GLP-1 adherence data; and Marion Webb, Hillary Lin’s evidence-based longevity care;

]]> 1103 no Digital Health Roundup: Oura Plans IPO, FDA’s Home Health, Digital Tools For Alzheimer’s Detection In this month: Marion Webb highlights Oura’s IPO, new partnerships, and a class-action lawsuit. George Underwood discusses digital tools for early Alzheimer’s detection and Brian Bossetta FDA’s READI-Home Innovation Challenge. Shubham Singh interviews AI longevity firm BAiO. Wed, 16 Sep 2026 17:58:00 -0000 full Norstella In this month: Marion Webb highlights Oura’s IPO, new partnerships, and a class-action lawsuit. George Underwood discusses digital tools for early Alzheimer’s detection and Brian Bossetta FDA’s READI-Home Innovation Challenge. Shubham Singh interviews AI longevity firm BAiO. In this month: Marion Webb highlights Oura’s IPO, new partnerships, and a class-action lawsuit. George Underwood discusses digital tools for early Alzheimer’s detection and Brian Bossetta FDA’s READI-Home Innovation Challenge. Shubham Singh interviews AI longevity firm BAiO.

]]> 1262 no Medtech Insight Trailer Wed, 19 Aug 2026 17:32:00 -0000 trailer Norstella 65 no Digital Health Roundup: CE Mark For Vision-Restoring Implant, AI Chatbot Rules, MS Deal Science Corp.'s PRIMA brain-computer interface receives CE mark for restoring central vision in AMD patients. Viz.ai partners with Cortechs.ai on MS tracking. AMA urges Congress to regulate mental health AI chatbots. MedLink earns Mayo Clinic Platform qualification. Thu, 06 Aug 2026 13:29:00 -0000 full Norstella Science Corp.'s PRIMA brain-computer interface receives CE mark for restoring central vision in AMD patients. Viz.ai partners with Cortechs.ai on MS tracking. AMA urges Congress to regulate mental health AI chatbots. MedLink earns Mayo Clinic Platform qualification. Science Corp.'s PRIMA brain-computer interface receives CE mark for restoring central vision in AMD patients. Viz.ai partners with Cortechs.ai on MS tracking. AMA urges Congress to regulate mental health AI chatbots. MedLink earns Mayo Clinic Platform qualification.

]]> 712 no The Insight Room: Catching the Deadliest Cancer Earlier - Inside the PRECEDE–Azenta Partnership Pancreatic cancer has the lowest survival rate of any major cancer — just 13%, largely because it's so hard to catch early. Changing that takes more than a lab breakthrough. It takes the unglamorous infrastructure to collect, track, and safeguard patient samples across dozens of institutions, reliably enough that researchers can trust what they find. In this episode, host Krishna talks with Margaret Caspler, President and CEO of the PRECEDE Foundation — a consortium of more than 65 academic medical centers working to raise pancreatic cancer survival from 13% to 50% — and Kathi Shea, Chief Client Solutions Officer for Repository at Azenta Life Sciences, who has spent three decades in biorepository science. Together they explore why early detection has lagged, what it takes to run a biospecimen network at scale, and how a public-private partnership can do what neither side could alone. Follow Medtech Insight to stay ahead of every shift in the device and diagnostics landscape. Mon, 22 Jun 2026 08:27:00 -0000 full Norstella Pancreatic cancer has the lowest survival rate of any major cancer — just 13%, largely because it's so hard to catch early. Changing that takes more than a lab breakthrough. It takes the unglamorous infrastructure to collect, track, and safeguard patient samples across dozens of institutions, reliably enough that researchers can trust what they find. In this episode, host Krishna talks with Margaret Caspler, President and CEO of the PRECEDE Foundation — a consortium of more than 65 academic medical centers working to raise pancreatic cancer survival from 13% to 50% — and Kathi Shea, Chief Client Solutions Officer for Repository at Azenta Life Sciences, who has spent three decades in biorepository science. Together they explore why early detection has lagged, what it takes to run a biospecimen network at scale, and how a public-private partnership can do what neither side could alone. Follow Medtech Insight to stay ahead of every shift in the device and diagnostics landscape. Pancreatic cancer has the lowest survival rate of any major cancer — just 13%, largely because it's so hard to catch early. Changing that takes more than a lab breakthrough. It takes the unglamorous infrastructure to collect, track, and safeguard patient samples across dozens of institutions, reliably enough that researchers can trust what they find.

In this episode, host Krishna talks with Margaret Caspler, President and CEO of the PRECEDE Foundation — a consortium of more than 65 academic medical centers working to raise pancreatic cancer survival from 13% to 50% — and Kathi Shea, Chief Client Solutions Officer for Repository at Azenta Life Sciences, who has spent three decades in biorepository science. Together they explore why early detection has lagged, what it takes to run a biospecimen network at scale, and how a public-private partnership can do what neither side could alone.

Follow Medtech Insight to stay ahead of every shift in the device and diagnostics landscape.

]]> 2395 no Ambu CEO Britt Meelby Jensen on EU competitivity and compromise Mon, 01 Jun 2026 03:30:00 -0000 full Norstella 106 no MHRA’s Rob Reid updates on timings for CE marking, pre-market SI and possible EU MDR outcomes MHRA’s Rob Reid spoke to Ashley Yeo at MTF 2026 on issues affecting UK and Great Britain medtech regulation Fri, 22 May 2026 08:08:00 -0000 full Norstella MHRA’s Rob Reid spoke to Ashley Yeo at MTF 2026 on issues affecting UK and Great Britain medtech regulation MHRA’s Rob Reid spoke to Ashley Yeo at MTF 2026 on issues affecting UK and Great Britain medtech regulation

]]> 257 no ABHI's Steve Lee on the UK MHRA's frictionless regulatory future for the UK The MHRA’s spring 2026 CE-marking consultation, the progress of UK medtech statutory instruments and the European Commission’s proposed revision of the MDR and IVDR were top of mind for the Association of British HealthTech Industries' Steve Lee as he did the rounds – and the panels – at the MedTech Forum 2026. Fri, 15 May 2026 14:29:00 -0000 full Norstella The MHRA’s spring 2026 CE-marking consultation, the progress of UK medtech statutory instruments and the European Commission’s proposed revision of the MDR and IVDR were top of mind for the Association of British HealthTech Industries' Steve Lee as he did the rounds – and the panels – at the MedTech Forum 2026. The MHRA’s spring 2026 CE-marking consultation, the progress of UK medtech statutory instruments and the European Commission’s proposed revision of the MDR and IVDR were top of mind for the Association of British HealthTech Industries' Steve Lee as he did the rounds – and the panels – at the MedTech Forum 2026.

]]> 523 no